KRT17 anticorps (full length)

N° du produit ABIN7878485

Cet anticorps Souris Monoclonal détecte spécifiquement KRT17 dans WB et IHC (p). Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour KRT17 anticorps (full length) (ABIN7878485)

Antigène: KRT17 (Keratin 17 (KRT17))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp KRT17 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: KRT17-4604

Détail du produit anti-KRT17 anticorps

Épitope: full length

Fonction: Cytokeratin 17 Antibody / CK17 / Keratin 17

Purification: Protein A/G affinity

Immunogène: Recombinant full-length human KRT17 protein was used as the immunogen for the Cytokeratin 17 antibody.

Isotype: IgG1, kappa

Information d'application

Indications d'application: Optimal dilution of the Cytokeratin 17 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the Cytokeratin 17 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur KRT17

Antigène: KRT17 (Keratin 17 (KRT17))

Autre désignation: Cytokeratin 17

Sujet: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

UniProt: Q04695